• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

Among Cannabis Stocks, Here's a Breath of Fresh Ayr

Ayr Strategies is expanding in a contracting market.
By DEBRA BORCHARDT
Oct 06, 2020 | 06:31 AM EDT
Stocks quotes in this article: AYRSF, MMNFF, CGC, ACRHF

It wasn't that long ago that many cannabis companies were expanding their empires and competing with each other over who was the biggest. The most states! The most licenses! The biggest greenhouse square footage! Then as capital tried up, the reverse took over and those same companies began a race to contract.

The phrases "targeted approach" and "focus on profitability" are the new rallying cries for these once-expanding businesses. Now, the setup is for a classic pioneer vs. settlers environment. Ayr Strategies (AYRSF)  is coming in hot as a settler. The description is based on the business thesis that pioneers explore undeveloped concepts and go into uncharted territory. They make future success possible, but fail a lot. The settlers can take an idea and turn it into a product. They can take something not well thought through and finesse it into a profitable creation. The settlers can learn and build on the pioneer's mistakes.

Relative newcomer Ayr Strategies is doing just that. As companies like MedMen (MMNFF) , Canopy Growth (CGC) and Acreage Holdings  (ACRHF) are scaling back and selling off assets, Ayr is making numerous acquisitions with more planned. Last week the company announced it was buying two operations in Ohio and Pennsylvania. Both markets are medical marijuana only, currently with Pennsylvania hitting $420 million in sales last year, while Ohio was clocking in at $58 million.

"We believe both represent potential high growth markets and/or transition to recreational sales given each state's large population," Canaccord Genuity analyst Bobby Burleson wrote. "We anticipate a significant land grab among operators in the near term trying to enter populous markets with limited existing business (already being seen in Pennsylvania) and believe assets in potential expansion markets will become more expensive in the near term."

Burleson thinks that Ayr's early entry to both markets will give them a significant advantage relative to later-arriving entrants. He has a about $18.85 market price on the CSE trading stock, which was lately selling at $13.75. Ayr, which is also in Massachusetts and Nevada, is hinting at more expansion news to come.

In Ohio, Ayr has signed a definitive purchase agreement for an operational processing facility and has an agreed non-binding term sheet regarding exclusive management rights over a "level 1" cultivation license -- the largest canopy license in the state. The deal is valued at $18.2 million and consists of $10.2 million in cash and $8 million in convertible notes. These are the first steps toward establishing a vertically integrated operation in the state.

The cultivation facility, which is approximately 58,000 square-feet, is under construction and the roughly 9,000 square-foot processing facility is fully operational. Following the closing and completion of the initial phase of the level 1 cultivation facility build-out, Ayr has the flexibility to further expand canopy subject to the approval of the Ohio Department of Commerce. Prior to the pandemic, momentum was building for adult-use legislation heading to Ohio voters. Vireo Health also agreed to sell its affiliated company, Ohio Medical Solutions, LLC for $4.85 million to Ayr.

Ayr was already in the state of Pennsylvania, so this latest move is more of an expansion. The company is buying a grower-processor with a 38,400 ft cultivation and extraction facility that is approved as operational and has the capacity to expand to 74,000 square feet. The company is paying $20.8 million which includes $16.7 million of cash, $2.1 million in stock and $2.0 million in seller notes. This follows an August announcement of the purchase of a vertical facility that has the right to open six dispensaries (three planned for early 2021). These two deals will make Ayr one of the largest operators in the state.

Cash On Hand

Burleson did note that Ayr has now committed $54 million in cash for these acquisitions and as of July only had $17 million in cash with third quarter cash estimated to rise to $27 million, meaning the company will probably need to raise more capital. Ayr Strategies stock was the product of a special purpose acquisition company, and began publicly trading last year in May. Its market cap is currently $329 million.

This May, the company reported that its revenue increased 4% sequentially in the first quarter ending in March to $33.6 million. The company did note that sales began to decline in March due to the Covid-19 related closures. The company also reported a net income of $3.3 million after a foreign currency translation. The earnings per share were $0.06 basic and $0.05 diluted.

Ayr also made improvements on its loss from operations as it trimmed that number from a loss of $16.9 million in the fourth quarter to a loss of $4.9 million in the first quarter. The adjusted earnings before interest, taxes, depreciation, and amortization was $8.4 million, which dropped from the fourth quarter's $9.2 million due to the Covid closures.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Borchardt had no positions in any securities mentioned.

TAGS: Investing | Investing basics | Stocks | Canada | Cannabis

More from Stocks

Stock Market Continues to Defy Conventional Wisdom

James "Rev Shark" DePorre
Jan 22, 2021 5:04 PM EST

Concerns about the action being overheated remain, but rotational action keeps the momentum going.

AMC Is a High Risk, High Reward Play

Timothy Collins
Jan 22, 2021 2:15 PM EST

Short and sweet: This is based on the high running emotions of the markets. There's little to it beyond that.

GoodRx Needs a Shot in the Arm to Improve Its Outlook

Bruce Kamich
Jan 22, 2021 2:03 PM EST

IPOs in recent months have done extremely well -- not so GDRX.

GameStop and the Dangerous Game of Gamma Squeezes

Timothy Collins
Jan 22, 2021 1:26 PM EST

What happened after Citron Research posted a video about GameStop is very troubling.

Stocks Are Well Off Early Lows, but There's Still Quite a Bit of Weakness

James "Rev Shark" DePorre
Jan 22, 2021 1:18 PM EST

There is still strong interest in stock picking which is the most positive thing about this market.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:01 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    I'll discuss price targets in my Saturday column.
  • 07:54 AM EST GARY BERMAN

    Friday Morning Fibocall for 1/22/2021

    SPX (Long-Term View) The 1/21/21 NEW high @ 3861...
  • 11:16 AM EST CHRIS VERSACE

    Worst Stocks to Buy for the Biden Presidency

    Biden's take on the minimum wage, likely moves on ...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login